|
|
Article: FDA Awards PTC Therapeutics Orphan Products Development Grant for the Development of PTC124 in Duchenne Muscular Dystrophy.
- Article from:
- PR Newswire
- Article date:
- October 19, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Preliminary Data to be Presented at Parent Project UK Muscular Dystrophy Conference -
SOUTH PLAINFIELD, N.J., Oct. 19 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery and development of small-molecule drugs targeting post-transcriptional control mechanisms, today announced it has been awarded a two-year grant from the Office of Orphan Products Development (OOPD) Grant Program of the U.S. Food and Drug Administration (FDA). The grant will support the patient-related costs of the company's ongoing U.S.-based Phase 2 clinical trial of PTC124 for the treatment of nonsense-mutation-mediated Duchenne muscular ...